Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
... NEW YORK, Sept. 20 /PRNewswire-FirstCall/ --
callisto Pharmaceuticals,
Inc. (Amex: KAL; FWB: CA4), a dev...
relapsed or refractory multiple myeloma patients.
callisto earlier
announced in June, 2006 interim data from ... abdominal pain and valvular heart disease. About
callisto Pharmaceuticals, Inc. ...
Callisto Reports on Second-Quarter 2007 Milestones
...grams
NEW YORK, Aug. 8 /PRNewswire-FirstCall/ --
callisto Pharmaceuticals,
Inc. (Amex: KAL; FWB: CA4), a dev...g (synthetic molecule)
of uroguanylin developed by
callisto scientists, and is proprietary to
Callisto. Guanil... being
evaluated in animal models of GI disorders.
callisto plans to initiate
clinical trials of Guanilib in e...
Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
... NEW YORK, Aug. 9 /PRNewswire-FirstCall/ --
callisto Pharmaceuticals,
Inc. (Amex: KAL; FWB: CA4), a dev...erested in participating in this trial." Currently
callisto has enrolled
31 patients of the 40 subjects planne...
relapsed or refractory multiple myeloma patients.
callisto earlier
announced in June, 2006 interim data from ...
Callisto Intends to Move Guanilib into Clinical Trials in
Ulcerative Colitis
...e drug is currently in preclinical
development and
callisto intends to move the drug into clinical
trials in u...proprietary program
that was developed in-house by
callisto scientists and the company
owns 100% of the worldw...ib in GI inflammatory diseases
and colon cancer.
callisto believes that Guanilib is presently the best
physi...
Callisto Pharmaceuticals Announces Publication of Research Article
on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
..., S. Hong, F. Samaniego, J.
Romaguera and Q. Yi.
callisto is a biopharmaceutical company focused on the
deve...cute
leukemia, a currently incurable blood cancer.
callisto initiated a
clinical trial of L- Annamycin in pedi...compared to currently available drug
alternatives.
callisto also has drugs in preclinical development
for gast...